With a one year PEG ratio of 0.47, 10x Genomics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.11% of US stocks.
TXG's went public 1.23 years ago, making it older than just 1.32% of listed US stocks we're tracking.
TXG's price/sales ratio is 59.49; that's higher than the P/S ratio of 95.91% of US stocks.
Stocks that are quantitatively similar to TXG, based on their financial statements, market capitalization, and price volatility, are ESTC, WIX, GWPH, PEGA, and SMAR.
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
A report by The Insight Partner's on the global Single-Cell Genome Sequencing (SCGS) market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive
10x Genomics (TXG) has priced upsized public offering of its 4M (from 3.5M) Class A common stock at $110.00/share, at a discounted price from Sept. 10 close of $113.51.Underwriters' over-allotment is an additional 600K shares.Closing date is September 15.10x Genomics has rebounded from March lows of around $51 to around...